Citations

Clear

5210 citation(s) found for "Wang, Yu".

Antigen-Presenting B-Cell Signature Predicts Response and Survival in HER2-Positive Breast Cancer
Ku, Wen‐Hui, Lin, Chia-Jen, Wu, Bogang, Wu, H. , Yen, Tzu‐Chun, Lo, Chiao , Wang, Ming-Yang, Huang, Chiun-Sheng, Lin, Po‐Han , Lien, Huang‐Chun , Tsai, Li‐Wei , Wang, Ming-Yang, Kuo, Sung‐Hsin , Huang, Chiun‐Sheng

Mayo Clinic

No container title available | May 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-9236222/v1 Get It

Abstract Neoadjuvant therapy (NAT) with HER2-targeted agents is the standard treatment for patients with HER2-positive early breast cancer (HER2 + EBC). Although high levels of tumor-infiltrating lymphocytes (TILs) are associated with higher pathologic complete response (pCR) rates and improved recurrence-free survival (RFS), the specific immune components responsible remain unclear. In this study, pretreatment tumor biopsies from 188 patients receiving HER2-targeted NAT were analyzed. Univariate analysis revealed that enrichment of TIL-B cells in tumors, high HER2 mRNA and low ESR1 mRNA expression were linked to pCR (both p < 0.01). Multivariate analysis confirmed TIL-B-cell enrichment as an independent predictor of pCR. Mature IgD/IgM-high B cells, but not immature RAG1 + B cells, independently predicted pCR. Transcriptomic profiling identified 265 upregulated genes in pCR tumors enriched in MHC class II antigen presentation pathways. Immunofluorescence demonstrated increased spatial interaction of mature B cells with CD4 + T cells in pCR tumors, consistent with active antigen presentation. The antigen presenting B-cell signature, integrated mature B-cell and MHC II profile, was the strongest independent predictor of pCR (OR = 3.008, 95% CI: 1.196–7.544, p = 0.019) and was also significantly associated with improved RFS (HR = 0.109, 95% CI: 0.014–0.872), highlighting B-cell–mediated antigen presentation as a clinically relevant biomarker in HER2 + EBC.
Predictive Modeling of Early Mortality After Left Ventricular Assist Device Implantation: A Single-Center Exploratory Analysis
Lu, Shi , Liu, Junjiang , Liu, Dingqian , 郝光伟, Tu, Guowei , Guo, Kefang , Dong, L L, Huo, Ran , Lee, Aurora , Wang, Chunsheng, Sun, Xiaoning, Huo, Ran

Mayo Clinic

No container title available | May 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-9391241/v1 Get It

Abstract Background: Early postoperative mortality remains a major clinical challenge in left ventricular assist device implantation. Accurate preoperative identification of high-risk patients could optimize candidate selection and improve perioperative management. Methods: From February 2021 to March 2025, 60 patients who underwent LVAD implantation at Zhongshan Hospital, Fudan University were included in the present study. Early mortality was defined as death within 2 months postoperatively, a threshold derived from survival analysis showing a distinct early hazard phase. Preoperative demographic, echocardiographic, hemodynamic, and laboratory variables were evaluated. Predictor selection used least absolute shrinkage and selection operator (LASSO) logistic regression with 10-fold cross-validation, followed by multivariable Firth logistic regression. Internal validation employed bootstrap resampling (1,000 iterations). Results: The mean age was 55 ± 10 years, and 50 (83%) patients had dilated cardiomyopathy. Kaplan–Meier analysis indicated an early hazard phase, with all deaths occurring by ~ 1.7 months after implantation. LASSO selected age, MELD-XI, passive cardiac index (PasCI), and mixed venous oxygen saturation (SvO₂) for multivariable modeling. In the final Firth model, lower SvO₂ (odds ratio [OR] 0.92; 95% CI 0.83–1.00; p = 0.048) and older age (OR 1.13; 95% CI 1.00–1.35; p = 0.059) were associated with higher early mortality. Internal validation yielded an optimism-adjusted AUC of 0.84. Conclusions: In this exploratory study, lower preoperative SvO₂ and older age were the principal predictors of early mortality after LVAD implantation. Our internally validated risk assessment model supports preoperative risk prediction and stratification; however, confirmation in larger, multicenter cohorts is warranted before broader adoption. (246/250)
Prevalence and predictors of extra-aortic aneurysms in Marfan syndrome
Nabi, Hussein Abdul , Dreher, Luke Arnulfo , VanDolah, Hunter , Bcharah, Hend , Bcharah, George , Kanaan, Christopher, Ibrahim, Ramzi, Abdelnabi, Mahmoud, Baudhuin, Linnea M. , Wang, Yuxiang, Masry, Hicham Z El, Ayoub, Chadi, Shamoun, Fadi , Abdul Nabi, Hussein , El Masry, Hicham Z, Shamoun, Fadi E., Dreher, Luke , Kanaan, Christopher , Ibrahim, Ramzi , Abdelnabi, Mahmoud , Masry, Hicham El

Mayo Clinic

Heart | May 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: heartjnl-2025-327408

10.1136/heartjnl-2025-327408 | PMID 42103457 Get It

Background The prevalence and clinical correlates of extra-aortic vascular disease in Marfan syndrome remain incompletely defined, and current surveillance strategies primarily target the thoracic aorta. Methods We conducted a multicentre retrospective cohort study of 783 patients with Marfan syndrome across three tertiary centres, with systematic chart and imaging adjudication to define aneurysm and dissection distribution. Results Extra-aortic aneurysms were identified in 32% of patients, most commonly involving the iliac, carotid and subclavian arteries. Extra-aortic dissections occurred in 5.2%. Extra-aortic aneurysms clustered strongly with markers of advanced aortic disease, including abdominal aortic aneurysm (adjusted OR 3.48), prior aortic dissection (OR 3.39) and extra-aortic dissection (OR 4.44), as well as age >40 years and male sex. Genetic confirmation status was not associated with extra-aortic aneurysm presence. Conclusions Extra-aortic vascular involvement is common in Marfan syndrome and closely linked to advanced aortic pathology. These findings support risk-stratified vascular imaging beyond the thoracic aorta in higher-risk patients.
Placebo Response in Phase II-III Symptom Intervention Studies: A Focus on Chemotherapy-Induced Peripheral Neuropathy and Associated Neuropathic Pain
Zahrieh, David, Satele, Daniel , Haamankuli, Hiboombe , Le‐Rademacher, Jennifer , Lee, M E, Liu, Heshan, Diaz-Cobo, Julian, Shen, Shu‐En , Chow, S F, Lustberg, Maryam, Ruddy, Kathryn J. , Smith, Elizabeth , Lee, Minji K. , Zahrieh, David , Chow, Selina , Zahrieh, David , Le-Rademacher, Jennifer G , Lee, Minji K , Shen, Shu-En , Chow, Selina , Ruddy, Kathryn J , Lavoie Smith, Ellen M , Zahrieh, David , Wang, Xin Shelley , Lustberg, Maryam B.

Mayo Clinic

Cancers | May 11, 2026 | Volume: 18 | Issue: 10 | Pages: 1514

10.3390/cancers18101514 | PMID 42192875 Get It

Background/Objectives. Decades of research have failed to uncover effective approaches to prevent chemotherapy-induced peripheral neuropathy (CIPN), a common side effect of neurotoxic chemotherapy. Increased interest in placebo response as a potentially under-recognized confounder in CIPN trials was recently sparked by the results of a multisite NCI-funded phase II-III CIPN prevention study of duloxetine, a promising serotonin–norepinephrine reuptake inhibitor that enhances pain-inhibitory mechanisms within the central nervous system. Study findings revealed high and nearly equivalent response rates in three randomized treatment groups—little to no CIPN was reported by 65.2%, 66.0%, and 68.0% of study participants who received duloxetine 30 mg, 60 mg, or placebo treatment, respectively. Methods. We performed a meta-analysis of placebo response rates from seven randomized, double-blinded, placebo-controlled trials conducted over the past 20 years and comprising 191 placebo participants that were specifically testing interventions for oxaliplatin- and paclitaxel-induced peripheral neuropathy and that serially collected patient responses on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Chemotherapy-Induced Neuropathy questionnaire. Additionally, we sought to identify trial- and patient-specific factors that predicted higher placebo response rates from a participant-level pooled analysis. Results. The placebo response rate was 10.0% [95% CI: 5.8%, 16.6%] when response was defined more conservatively as patients reporting no neuropathy at all. When the placebo response was defined more broadly based on patients reporting no or a little neuropathy, the placebo response rate was higher (39.6% [95% CI: 27.4%, 53.2%]). Male participants, receipt of oxaliplatin, and a 2:1 randomization ratio favoring the intervention arm were individually associated with a higher placebo response. Conclusions. High placebo response rates can threaten scientific progress toward identifying effective treatments for cancer treatment-associated side effects, like CIPN. Careful attention to study design factors, participant eligibility, and patient and research staff expectations may help to minimize placebo response rates in future CIPN intervention studies.
AEGIS reveals epitope- and clone-resolved convergence of CNS B and T cell autoreactivity in ROHHAD
Bodansky, Aaron, Ahyong, Vida , Dayao, Monica, Asaki, James , Vanasupa, ShiLu, Dandekar, Ravi , Chen, Shini, Sabatino, Joe, Klauer, Sam, Knudsen, Giselle, Valenzuela, Carlos Lizama, Mccutcheon, Krista, Zorn, Kelsey, Sidhu, Sukhman, Yu, David, Garcia, Samantha, Quandt, Zoe, Wang, Chung-Yu, Rojas, Bryan Castillo, Tilton, Iris, Citron, Y. Rose, Sharathchandra, Akshay, Gerungan, Chloe, Tomko, Stuart, McKeon, Andrew, Cooper, Tiffany, Harms, Meagan, Fancy, Stephen P J, Green, A J, Caliskan, Ilay , Cadwell, Cathryn R., Ostrem, Bridget EL, Karalius, Mary, Braun, Lindsay, Gupta, Sasha , Francisco, Carla, Peng, Greta, Reddy, A. O., Nash, Kendall, Mandel‐Brehm, Caleigh , Arnold, Thomas D. , Anderson, Mark S., Gerdts, Josiah, DeRisi, Joseph L., Bodansky, Aaron , Dayao, Monica T. , Knudsen, Giselle M. , Quandt, Zoe , Castillo-Rojas, Bryan , Citron, Y. Rose, Tomko, Stuart R. , Robbins, Nathaniel M. , McKeon, Andrew , Cooper, Tiffany P. , Harms, Meagan, Gomez, Refujia , Fancy, Stephen P.J. , Cadwell, Cathryn René , Ostrem, Bridget E.L. , Braun, Lindsay C., Francisco, Carla , Peng, Greta Solinap , Reddy, Alyssa , Pleasure, Samuel J , Anderson, Mark S. , Wilson, Michael R. , DeRisi, Joseph L

Mayo Clinic

No container title available | May 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.05.06.722823 | PMID 42182119 Get It

Autoimmune diseases arise when B and T lymphocytes lose tolerance to self. Yet in most disorders, the underlying molecular determinants, including autoantibodies, epitopes and lymphocyte clones that drive tissue injury remain undefined. Rapid-onset obesity with hypothalamic dysfunction, hypoventilation and autonomic dysregulation (ROHHAD) is a rare and often fatal pediatric neuroendocrine syndrome with strong evidence of antigen-driven paraneoplastic autoimmunity, including association with the intracellular autoantigen ZSCAN1. However, the effector immune circuit and the epitope-level determinants operating within the hypothalamus and brainstem have remained unknown. To address this challenge in ROHHAD and more broadly in autoimmune disease, we developed the Autoimmune Epitope and immunoGlobulin/Immune-receptor identification System (AEGIS), an integrated framework that links immune repertoires to their cognate self-epitopes. AEGIS combines B cell and T cell receptor profiling from sites of tissue injury with high-resolution epitope mapping, direct sequencing of antigen-specific autoantibodies, in silico antibody-antigen folding, selection, and T cell antigen discovery. Applied to a deeply phenotyped child with ROHHAD, AEGIS revealed a compartmentalized, clonally restricted immune response in which brain-deposited IgG and expanded cerebrospinal fluid B cell and CD4 T cell clonotypes converged on shared ZSCAN1 epitopes, resolved to minimal determinants and peptide-MHC ligands. These findings provide a clone- and epitope-linked mechanistic map of ROHHAD autoimmunity and establish a generalizable framework for identifying candidate pathogenic clones and antigens across diverse autoimmune diseases.
Risk Reduction of Recurrent Cerebrospinal Fluid Leaks With Postoperative Intracranial Pressure Management: A Systematic Review
Wilson, Penny , Doucette, Madison M., Hossain, Ryan, Valencia, Bastien A. , Bernard, Christian J. , Wang, Zhen, Raymond, Mallory , Wilson, Prishae , Valencia‐Sanchez, Bastien A. , Raymond, Mallory J

Mayo Clinic

Otolaryngology–Head and Neck Surgery | May 10, 2026 | Volume: 175 | Issue: 2 | Pages: 292-303

10.1002/ohn.70290 | PMID 42106964 Get It

Abstract Objective To evaluate whether postoperative intracranial pressure–lowering interventions reduce recurrence of lateral skull base spontaneous cerebrospinal fluid leaks after surgical repair. Data Sources Ovid MEDLINE, Embase, Cochrane CENTRAL, Web of Science Core Collection, and Scopus were searched from inception through April 7, 2025. Review Methods The review followed the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines and included studies of adults with lateral skull base spontaneous cerebrospinal fluid leaks undergoing primary repair where postoperative intracranial pressure–lowering interventions were specified. Pooled recurrence rates were calculated by intervention type and compared with cohorts that did not receive intracranial pressure–lowering therapy. Results Thirty‐six studies including 687 patients (737 cases) met inclusion criteria. Six comparative cohorts (34 treated, 155 untreated) showed no significant difference in recurrence (risk ratio 1.16, 95% confidence interval [CI]: 0.14–9.76; I 2 = 0%). Across 82 intervention‐only cases, recurrence occurred in three (pooled proportion 0.10, 95% CI: 0.04–0.26; I 2 = 0%). Among 650 control‐only cases, 45 recurred (pooled proportion 0.09, 95% CI: 0.07–0.12; I 2 = 0%). No heterogeneity was observed across pooled analyses. Conclusion Available evidence does not support universal postoperative intracranial pressure–lowering therapy after lateral skull base spontaneous cerebrospinal fluid leak repair. Limited observational data suggest acetazolamide may be associated with lower recurrence, whereas lumbar drainage has not demonstrated sustained benefit. Given the heterogeneity in patient selection and intervention practices, postoperative management should be individualized. Future prospective studies are needed to better define the role of targeted therapy in high‐risk patients.
Associations and differences between occupational burnout and depression in large studies of U.S. physicians
Shanafelt, Tait D, West, Colin P. , Sinsky, Christine, Tutty, Michael, Carlasare, Lindsey E. , Trockel, Mickey, Shanafelt, Tait D. , Shanafelt, Tait D , West, C P , Dyrbye, Liselotte N. , Sinsky, Christine A. , Tutty, Michael , Wang, Hanhan , Trockel, Mickey

Mayo Clinic

Academic Medicine | May 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/acamed/wvag126 | PMID 42103956 Get It

Abstract Purpose To evaluate the correlation between occupational burnout and depression, frequency with which they coexist, how often 1 condition may be present in the absence of the other, and their association with suicidal ideation. Method The authors conducted a secondary analysis of cross-sectional national surveys of practicing U.S. physicians (conducted October 19, 2023, to March 3, 2024) and residents/fellows (“trainees”; conducted November 30, 2023, to January 2, 2024). They measured correlation between emotional exhaustion (EE) and depersonalization (DP) scores using the Maslach Burnout Inventory and depression T-scores using the National Institutes of Health Patient Reported Outcomes Measurement Information System Depression scale. Results A total of 5993 practicing physicians and 2676 trainees were included in the analysis. The pooled R2 value between EE and depression scores for physicians and trainees was 0.42 (P &lt; .001) and between DP and depression scores was 0.28 (P &lt; .001). Among the 4087 practicing physicians with normal depression scores, 1201 (29.4%) had high EE and/or high DP. Among the 1601 trainees with normal depression scores, 485 (30.3%) had high EE and/or high DP. On multivariable logistic regression adjusting for age, gender, relationship status, and work hours, each 1-point increase in depression T-score was associated with 15% higher odds of suicidal ideation among practicing physicians (OR 1.15; 95% CI, 1.13–1.17; P &lt; .001) and trainees (OR 1.15, 95% CI, 1.13–1.17; P &lt; .001). No statistically significant association between EE or DP scores and suicidal ideation was observed. Conclusions Occupational burnout and depression are correlated but distinct constructs with distinct outcomes. Less than half the variation in burnout is explained by depression (and vice versa). Population health approaches to improve physician well-being should address both conditions. Organizational efforts should go beyond providing support for individuals experiencing distress and also address the work environment factors that contribute to it.
CDCP1 Deletion Protects Against Pressure Overload-Induced Cardiac Dysfunction and Fibrosis in Mice
Pereira, Naveen, Ghazal, Rachad, wang, Min, Cao, Jenny Jia Ling, Wang, Li , Sherman, William , John, August, Vyas, Hridyanshu , Roos, Carolyn, Huang, Runqing, Ördög, Tamás , Trussoni, Christy, Lim, Do Young , Sinagra, Gianfranco, Weinshilboum, Richard M. , Liu, Duan , Lambert, Laura , Miller, Jordan , Tschumperlin, Daniel, Srinivas, Akshatha N. , Sherman, Will A , Ordog, Tamas , Wang, Chen , Baker, Darren J , Weinshilboum, Richard M. , Liu, Duan , Lambert, Laura J, Pereira, Naveen, Ghazal, Rachad , Cao, Jenny Jia Ling , Wang, Li, Marín-Goñi, Irene , Wang, Chen , Trussoni, Christy E. , Baker, Darren J. , Sinagra, Gianfranco , Tschumperlin, Daniel J.

Mayo Clinic

No container title available | May 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-9236741/v1 | PMID 42147194 Get It

Abstract Human genomic studies link reduced CUB domain-containing protein 1 (CDCP1) expression with myocardial recovery in heart failure. While CDCP1 regulates cardiac fibroblast proliferation in vitro, it’s in vivo role in cardiac fibrosis remains unclear. Using a Cdcp1 -knockout (KO) angiotensin II/phenylephrine mouse model, we show that Cdcp1 deletion reduces echocardiographic left ventricular mass, histologic cardiac fibrosis, and pro-fibrotic gene expression, along with decreased fibroblast activation and inflammatory markers. Spatial transcriptomics identified a pressure overload–expanded fibroblast subpopulation enriched for growth factor and TGF-β signaling (FB5), which was markedly attenuated in Cdcp1 -KO hearts, alongside reduction of a pro-inflammatory cardiomyocyte subtype (CM4). Complementary studies in human ventricular fibroblasts demonstrate that CDCP1 knockdown reduced extracellular matrix gene expression and collagen I deposition. These findings establish CDCP1 as a regulator of cardiac fibrotic remodeling in vivo and open avenues for its further investigation as a potential therapeutic target.
Development of a nomogram for predicting incident heart failure and all-cause mortality in patients with chronic kidney disease: a 3-year follow-up study
Jiang, Yuxin, Song, Xiaotong, Liao, Hongfei, Sun, C J , Zhang, Dingxin , Zhou, Runzhe, Yang, Xiangjie, Wang, Xiaoxia, Li, Dashan, Zhang, Jin, Li, Yan, Wang, Ying, Zhou, Xinyuan , Li, Dashan

Mayo Clinic

Frontiers in Medicine | May 8, 2026 | Volume: 13 | Issue: No issue available | Pages: No page available

10.3389/fmed.2026.1784717 | PMID 42180711 Get It

Background Chronic kidney disease (CKD) confers a substantially elevated risk of cardiovascular (CV) mortality, primarily driven by heart failure (HF) and other CV complications. This study aimed to develop a nomogram for predicting incident HF and all-cause death in patients with CKD, and further identify individuals at high risk of these outcomes. Methods We prospectively recruited 440 patients with CKD stages 3–5 and preserved ejection fraction (LVEF) from a nephropathy center between November 2020 to September 2024. Baseline clinical and demographic characteristics, biochemical and echocardiographic parameters, and data from quality-of-life scales were collected. Key predictors were identified using univariate Cox regression, Lasso, Random Forest, and XGBoost algorithms; these identified predictors were then integrated into a nomogram via multivariate Cox regression. Model performance was assessed using the C-index, ROC analysis, and calibration plots. Results Over 29 months (IQR 24–35), 104(23.6%) patients met the primary composite endpoints, which included 62(14.1%) incident HF and 42(9.5%) all-cause death. After selecting variables through forward stepwise regression, age[HR 1.030, P = 0.016], growth differentiation factor 15(GDF-15) [HR 1.076, P &lt; 0.001], lipoprotein(a)[Lp(a)] [HR = 1.011, P = 0.002], ferritin(FER) [HR = 1.009, P = 0.030], and EuroQol-5D (EQ-5D) score [HR 0.099, P = 0.015] were utilized to construct the nomogram. In the training cohort, the model achieved a C-index of 0.772. For temporal validation, time-dependent area under the ROC curve(AUC) values further confirmed its accuracy: 0.779 (95%CI, 0.696–0.863) at 24 months, 0.816(95%CI, 0.743–0.888) at 27 months, 0.836(95%CI, 0.768–0.903) at 32 months, and 0.850(95%CI, 0.771–0.929) at 36 months. Decision curve analysis (DCA) also demonstrated sustained clinical utility across a broad range of threshold probabilities. Conclusion This study identified specific predictors of HF and all-cause mortality in CKD patients. This model has enhanced predictive ability for early identification of these risks, thereby facilitating timely clinical interventions to improve the prognosis of CKD patients.
Real-time AI integration for MR to detect artifacts and guide pulse sequence adaptations
Gudmundson, Aaron T. , Shams, Zahra , Gad, Abdelrahman , Wang, Shuyuan , Simičić, Dunja , Murali-Manohar, Saipavitra , Simegn, Gizeaddis Lamesgin , Özdemir, Ipek , Davies-Jenkins, Christopher W. , Song, Yulu , Yedavalli, Vivek , Demirel, Ömer Burak , Wang, Shuyuan , Simegn, Gizeaddis L , Yedavalli, Vivek S , Oeltzschner, Georg , Sulam, Jeremias , Ganji, Sandeep K , Edden, Richard A E , Murali‐Manohar, Saipavitra , Özdemir, İpek , Davies‐Jenkins, Christopher W. , Schär, Michael

Mayo Clinic

No container title available | May 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.05.04.722724 | PMID 42146385 Get It

Abstract This work presents a first-of-its-kind artificial intelligence (AI-)integrated MR pulse sequence that detects out-of-voxel (OOV) artifacts in real-time (within-TR) and responds prospectively by updating the crusher gradient scheme. Per Excitation Real-time Execution & Guided Responses with Integrated Neural-network Evaluation (PEREGRINE), allows for deployment of deep learning models and pulse sequence updates. In this study, PEREGRINE operated a time-domain (TD) and frequency-domain (FD) convolutional autoencoder that detect OOV artifacts. Scans without (AI-off) and with (AI-on) updates were collected from the medial prefrontal cortex of healthy volunteers using a MEGA-edited MRS experiment. The degree of OOV contamination (OOV Score) was quantified per transient based upon the prevalence of OOV signals in the TD and FD data. OOV Scores above a user-defined threshold triggered an update of the crusher gradient scheme, iterating through 48 permutations (6 axis transpositions × 8 polarity flips). Within each 2-second TR, PEREGRINE successfully provided single-transient OOV Scores and updated gradients accordingly. No difference was observed between the OOV Scores from the full (“Full” condition) AI-on and AI-off sessions due to the AI-on scan cycling over better and worse gradient permutations relative to the AI-off scan. However, the AI-on scan had significantly lower OOV Scores than the AI-off scan when selecting the transients where PEREGRINE persisted (“Dwell” condition) on a given gradient permutation. Ultimately, Fit Quality Number (FQN) from linear combination modeling improved significantly for the AI-on compared to the AI-off scan. PEREGRINE enabled an adaptive and AI-integrated sequence allowing for real-time evaluation and response to OOV artifacts, identifying gradient modifications that produced less OOV contamination. Graphical Abstract Graphical Abstract Summary PEREGRINE, Per Excitation Real-time Execution & Guided Responses with Integrated Neural-network Evaluation, allows for pulse sequence updates using on-scanner deployed neural networks. To demonstrate the utility, PEREGRINE was used to operate two neural networks (time/frequency domain), trained to detect out-of-voxel artifacts, during a MEGA-edited MRS experiment in the prefrontal cortex. When artifacts were detected, PEREGRINE updated the crusher gradients within the same TR. Real-time, adaptive, and AI-driven MR will provide a long-awaited solution for combatting artifacts and poor data quality. Graphical Abstract Figure